The Chronic Effects of Beetroot Juice in Hypertensive Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We are interested in the effect of diet on blood pressure. Our previous research has shown that beetroot juice lowers blood pressure in healthy people. We now want to see if beetroot juice has this effect in people with high blood pressure. Beetroot juice is naturally rich in nitrate (also found in most other vegetables but particularly in green leafy vegetables). We think that it is the nitrate that lowers the blood pressure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Acute Effect of Beetroot Juice in Normal and Hypertensive Subjects

NCT01236872

Hypertension

COMPLETED NA

Inter-individual Variation in the Blood Pressure Lowering Effects of Dietary Nitrate

NCT05514821

Blood Pressure

COMPLETED NA

Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ Damage

NCT03088514

Hypertension

COMPLETED PHASE2

Acute Effects of Beet Juice Intake on the Vascular Function of Hypertensive Patients

NCT04020796

Hypertension

COMPLETED NA

A 2 Week, Crossover Trial of Dietary Nitrate in HTN

NCT02597010

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beetroot Juice

Group Type EXPERIMENTAL

beetroot juice

Intervention Type DIETARY_SUPPLEMENT

Beetroot juice 4 weeks 250ml daily

Nitrate-free beetroot juice

Group Type PLACEBO_COMPARATOR

Nitrate-free beetroot juice

Intervention Type DIETARY_SUPPLEMENT

Nitrate-free beetroot juice 4 weeks 250ml daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

beetroot juice

Beetroot juice 4 weeks 250ml daily

Intervention Type DIETARY_SUPPLEMENT

Nitrate-free beetroot juice

Nitrate-free beetroot juice 4 weeks 250ml daily

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

1. Healthy adult male and females between 18 and 85 years of age, inclusive.
2. To be eligible, female subjects will be required to state that they are not pregnant, and will not become pregnant during the course of the study.
3. Body mass index (BMI) between 18 and 40 kg/m2
4. A signed and dated written informed consent prior to admission to the study
5. The subject is able to understand and comply with protocol requirements, instructions and protocol---stated restrictions.

and either of the following categories of blood pressure

Category 1---Pre---hypertensive SBP 130---139 or DBP 85---89 on no antihypertensives and will not commence antihypertensives during the course of the study.

Category 2---Grade 1 hypertensive SBP 140---159 or DBP 90---99 on no anti---hypertensives, no target organ damage (TOD), low cardiovascular disease (CVD) risk Category 3---Uncontrolled severe resistant (Grade 3) hypertensive with evidence of difficulty treating to target BP (140/85 or 130/80), with satisfactory adherence to at least one antihypertensive, but insufficient efficacy or intolerance of medications. (Category 3 patients may also be on aspirin and/or a stable dose of cholesterol---lowering medications e.g statins).

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

1. History of symptomatic coronary artery disease, stroke, or other known atherosclerotic disease.
2. History of chronic viral hepatitis (including presence of hepatitis B surface antigen or hepatitis C antibody), or other chronic hepatic disorders.
3. History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, 3x above the upper limit of normal or bilirubin 1.5x above the upper limit of normal at screening.
4. Renal impairment with creatinine clearance (eGFR) of \<50 ml/min at screening.
5. Current poorly controlled diabetes mellitus, defined as HbA1c \>10% at Screen.
6. Subjects with LDLc, \>7.5 mmol/l. Fasting TG level \>6mmol/l.
7. History of heart failure defined as NYHA class II --- IV or those with known severe LV dysfunction (EF\<30%) regardless of symptomatic status
8. History of malignancy within the past 5 years, other than non---melanoma skin cancer.
9. Current life---threatening condition other than vascular disease (e.g., very severe chronic airways disease, HIV positive, life---threatening arrhythmias) that may prevent a subject from completing the study.
10. Alcohol or drug abuse within the past 6 months.
11. Use of an investigational device or investigational drug within 30 days or 5 half---lives (whichever is the longer) preceding the first dose of study medication.
12. Subjects who will commence or who are likely to commence treatment with non---steroidal anti--- inflammatory drugs (NSAIDs) (other than aspirin), from screening until study completion.
13. Any non---stable dosing of ongoing medication regimens throughout the study trial.
14. The subject has a three---month prior history of regular alcohol consumption exceeding an average weekly intake of \> 28 units (or an average daily intake of greater than 3 units) for males, or an average weekly intake of \> 21 units (or an average daily intake of greater than 2 units) for females. 1 unit is equivalent to a half---pint (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine; or a positive alcohol breath test at the screening visit
15. A positive urine test for drugs of abuse (not related to known medications the subject is taking, i.e., codeine for pain management) or alcohol at screening or prior to study medication administration.
16. Any other subject whom the Investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities, expected study medication noncompliance, or subject's unwillingness to comply with all study---related study procedures).
17. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease).
18. Subjects with any acute infection, or significant trauma (burns, fractures).
19. Subjects who have donated more than 500 mL of blood within 56 days prior to the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No